CCO Independent Conference Coverage of CROI 2025: The Latest Updates in HIV *

This program summarizes key data and highlights from the 2025 Conference on Retroviruses and Opportunistic Infections (CROI).

Share

Program Content

Events

14 Capsule Summaries

Activities

TB Prevention With 3HP vs 6H
3-Mo Rifapentine and Isoniazid vs 6-Mo Isoniazid TB Preventive Therapy in People Living With HIV in Western Kenya
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 12, 2025

Expires: September 11, 2025

MK8591A052 Phase III Trial of DOR and ISL
MK-8591A-052: Phase III Trial of Switch From BIC/FTC/TAF to DOR/ISL in People Living With Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 12, 2025

Expires: September 11, 2025

MK8591A051
MK-8591A-051: Phase III Trial of Switch From Standard-of-Care ART to DOR/ISL in People Living With Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2025

Expires: September 12, 2025

CARES 96 Wk
CARES: 96-Wk Efficacy and Safety of LA CAB + RPV in Sub-Saharan Africa
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2025

Expires: September 12, 2025

PILLAR
PILLAR: Efficacy and Persistence of Long-Acting Cabotegravir in Real-world Phase IV Trial of HIV PrEP
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2025

Expires: September 12, 2025

PURPOSE 1 Adolescent Women
PURPOSE 1: Lenacapavir PrEP in Adolescent Cisgender Women
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 14, 2025

Expires: September 13, 2025

Lenacapavir, Teropavimab, and Zinlirvimab
Phase II Study Results of Lenacapavir, Teropavimab, and Zinlirvimab for People Living with Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 14, 2025

Expires: September 13, 2025

On Demand PrEP for Women
Utilizing PK/PD Modeling to Optimize On-Demand TDF/FTC PrEP Dosing for Women
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 14, 2025

Expires: September 13, 2025

DoxyPEP for STI Prevention
Doxycycline Postexposure Prophylaxis for STI Prevention in People on HIV PrEP Presenting for Sexual Health Visits
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 14, 2025

Expires: September 13, 2025

STOMP Tecovirimat
Phase III STOMP: Tecovirimat for the Treatment of Clade II Mpox
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 17, 2025

Expires: September 16, 2025

HPTN 094
HPTN 094: Mobile Unit Services Plus Peer Health Navigation vs Peer Health Navigation Alone for People Who Inject Drugs
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 17, 2025

Expires: September 16, 2025

BEe HIVe
BEe-HIVe: HepB-CpG HBV Vaccine Durability in People Living With HIV on ART ± Prior Vaccine History
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 17, 2025

Expires: September 16, 2025

HPTN 084 OLE
HPTN 084 OLE: HIV-1 RNA Screening in Women Receiving Long-Acting Cabotegravir for PrEP
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 17, 2025

Expires: September 16, 2025

Semaglutide in HIV
Semaglutide in People Living With HIV: Effect on Cognitive Function
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 17, 2025

Expires: September 16, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.